• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $PLX

    Protalix BioTherapeutics Inc. (DE)

    Subscribe to $PLX
    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is headquartered in Karmiel, Israel.

    IPO Year:

    Exchange: AMEX

    Website: protalix.com

    Peers

    $PLXP

    Recent Analyst Ratings for Protalix BioTherapeutics Inc. (DE)

    DatePrice TargetRatingAnalyst
    See more ratings

    Protalix BioTherapeutics Inc. (DE) SEC Filings

    See more
    • SEC Form 10-Q filed by Protalix BioTherapeutics Inc. (DE)

      10-Q - Protalix BioTherapeutics, Inc. (0001006281) (Filer)

      5/9/25 7:04:04 AM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Protalix BioTherapeutics Inc. (DE) filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Protalix BioTherapeutics, Inc. (0001006281) (Filer)

      5/9/25 6:57:27 AM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Protalix BioTherapeutics Inc. (DE)

      DEF 14A - Protalix BioTherapeutics, Inc. (0001006281) (Filer)

      4/30/25 4:30:32 PM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-3 filed by Protalix BioTherapeutics Inc. (DE)

      S-3 - Protalix BioTherapeutics, Inc. (0001006281) (Filer)

      4/28/25 5:00:54 PM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Protalix BioTherapeutics Inc. (DE) filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Protalix BioTherapeutics, Inc. (0001006281) (Filer)

      4/23/25 4:30:27 PM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Protalix BioTherapeutics Inc. (DE) filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

      8-K - Protalix BioTherapeutics, Inc. (0001006281) (Filer)

      3/17/25 5:19:35 PM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B5 filed by Protalix BioTherapeutics Inc. (DE)

      424B5 - Protalix BioTherapeutics, Inc. (0001006281) (Filer)

      3/17/25 4:33:31 PM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-K filed by Protalix BioTherapeutics Inc. (DE)

      10-K - Protalix BioTherapeutics, Inc. (0001006281) (Filer)

      3/17/25 7:18:30 AM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Protalix BioTherapeutics Inc. (DE) filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Protalix BioTherapeutics, Inc. (0001006281) (Filer)

      3/17/25 6:55:30 AM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Protalix BioTherapeutics Inc. (DE) filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - Protalix BioTherapeutics, Inc. (0001006281) (Filer)

      12/31/24 4:30:27 PM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Protalix BioTherapeutics Inc. (DE) Financials

    Live finance-specific insights

    See more

    Protalix BioTherapeutics Inc. (DE) Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    Protalix BioTherapeutics Inc. (DE) Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results

      Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, May 9, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended March 31, 2025, and provided a business and clinical update. "We had another solid quarter, with an increase in revenues from selling goods compared to the prior year quarter," said Dror Bashan, Protalix's President and Chief Executive Officer. "Given the promising resul

      5/9/25 6:50:00 AM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Protalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025

      Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel, May 5, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the quarter ended March 31, 2025 and provide a business and clinical update on May 9, 2025. Management will host a conference call to discuss the financial results and provide an update on recent corporate and regulatory developments. Conference Call Details: Date:   

      5/5/25 6:50:00 AM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Protalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business Results

      Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, March 17, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the fiscal year ended December 31, 2024, and provided a business and clinical update.     "2024 was a record year in revenues from selling goods for Protalix, as we experienced increases in all three of our revenue streams, Chiesi, Pfizer and Brazil," said Dror Bashan, Protalix's Presi

      3/17/25 6:50:00 AM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025

      Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel, March 10, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the fiscal year ended December 31, 2024 and provide a business and clinical update on March 17, 2025. Management will host a conference call to discuss the financial results and provide an update on recent corporate and regulatory developments. Conference Call Detai

      3/10/25 6:50:00 AM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results

      Company to host conference call and webcast today at 8:30 a.m. EST CARMIEL, Israel, Nov. 14, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE-American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended September 30, 2024, and provided a business and clinical update. "We are pleased to report that all eight cohorts of our phase I first-in-human study of PRX-115, our recombinant uricase candidate being developed for the treatment of uncontrolled gout, are now complete,

      11/14/24 6:50:00 AM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Protalix BioTherapeutics to Announce Third Quarter 2024 Financial and Business Results on November 14, 2024

      Company to host conference call and webcast at 8:30 a.m. EST CARMIEL, Israel, Nov. 7, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the quarter ended September 30, 2024 and provide a business and clinical update on November 14, 2024. Management will host a conference call to discuss the financial results and provide an update on recent corporate and regulatory developments. Conference Call Details

      11/7/24 6:50:00 AM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Protalix BioTherapeutics Reports Second Quarter 2024 Financial and Business Results

      Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, Aug. 14, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended June 30, 2024, and provided a business update. "In the second quarter, Protalix has made meaningful progress on our early-stage pipeline," said Dror Bashan, Protalix's President and Chief Executive Officer. "Results from the first seven cohorts of the phase I clinical

      8/14/24 6:50:00 AM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Protalix BioTherapeutics to Announce Second Quarter 2024 Financial and Business Results on August 14, 2024

      Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel, Aug. 7, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the quarter ended June 30, 2024 and provide a business and clinical update on August 14, 2024. Management will host a conference call with investors to discuss the financial results and provide an update on recent corporate and regulatory developments. Conference Call

      8/7/24 6:50:00 AM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Protalix BioTherapeutics Reports First Quarter 2024 Financial and Business Results

      Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, May 10, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended March 31, 2024, and provided a business and clinical update. "We are pleased to announce that initial top-line results from the first seven cohorts of the first-in-human phase I clinical trial of our recombinant uricase candidate, PRX-115, are encouraging, enabling us t

      5/10/24 6:50:00 AM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Protalix BioTherapeutics to Announce First Quarter 2024 Financial and Business Results on May 10, 2024

      Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel, May 3, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the quarter ended March 31, 2024 and provide a business and clinical update on May 10, 2024. Management will host a conference call with investors to discuss the financial results and provide an update on recent corporate and regulatory developments. Conference Call De

      5/3/24 6:50:00 AM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Bashan Dror bought $90,484 worth of shares (64,516 units at $1.40), increasing direct ownership by 95% to 132,516 units (SEC Form 4)

      4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)

      10/20/23 6:50:07 AM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. reiterated coverage on Protalix BioTherapeutics with a new price target

      HC Wainwright & Co. reiterated coverage of Protalix BioTherapeutics with a rating of Buy and set a new price target of $7.00 from $11.00 previously

      5/3/21 7:36:38 AM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Protalix BioTherapeutics Inc. (DE) Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Protalix BioTherapeutics Inc. (DE)

      SC 13G/A - Protalix BioTherapeutics, Inc. (0001006281) (Subject)

      10/25/24 4:23:48 PM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Protalix BioTherapeutics Inc. (DE) (Amendment)

      SC 13G/A - Protalix BioTherapeutics, Inc. (0001006281) (Subject)

      1/2/24 6:36:07 AM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Protalix BioTherapeutics Inc. (DE) (Amendment)

      SC 13G/A - Protalix BioTherapeutics, Inc. (0001006281) (Subject)

      1/3/23 6:01:32 AM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Protalix BioTherapeutics Inc. (DE)

      SC 13G - Protalix BioTherapeutics, Inc. (0001006281) (Subject)

      6/9/22 2:52:54 PM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Protalix BioTherapeutics Inc. (DE) (Amendment)

      SC 13G/A - Protalix BioTherapeutics, Inc. (0001006281) (Subject)

      2/14/22 3:14:51 PM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Protalix BioTherapeutics Inc. (DE) (Amendment)

      SC 13G/A - Protalix BioTherapeutics, Inc. (0001006281) (Subject)

      2/11/22 8:19:06 AM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Protalix BioTherapeutics Inc. (DE) (Amendment)

      SC 13G/A - Protalix BioTherapeutics, Inc. (0001006281) (Subject)

      1/31/22 7:16:56 AM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Protalix BioTherapeutics, Inc. (Amendment)

      SC 13G/A - Protalix BioTherapeutics, Inc. (0001006281) (Subject)

      7/30/21 6:02:00 AM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Protalix BioTherapeutics, Inc. (Amendment)

      SC 13G/A - Protalix BioTherapeutics, Inc. (0001006281) (Subject)

      6/15/21 9:19:55 AM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Protalix BioTherapeutics, Inc. (0001006281) (Subject)

      2/16/21 12:06:38 PM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Protalix BioTherapeutics Inc. (DE) Press Releases

    Fastest customizable press release news feed in the world

    See more

    Protalix BioTherapeutics Inc. (DE) Leadership Updates

    Live Leadership Updates

    See more
    • Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results

      Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, May 9, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended March 31, 2025, and provided a business and clinical update. "We had another solid quarter, with an increase in revenues from selling goods compared to the prior year quarter," said Dror Bashan, Protalix's President and Chief Executive Officer. "Given the promising resul

      5/9/25 6:50:00 AM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Protalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025

      Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel, May 5, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the quarter ended March 31, 2025 and provide a business and clinical update on May 9, 2025. Management will host a conference call to discuss the financial results and provide an update on recent corporate and regulatory developments. Conference Call Details: Date:   

      5/5/25 6:50:00 AM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025

      CARMIEL, Israel, March 24, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that its management will be participating in the iAccess Alpha Virtual Best Ideas Spring Investment Conference 2025, to be held virtually March 25-26, 2025. iAccess Alpha hosts virtual investor conferences featuring companies recommended by investors. These two-day events include webcast presentations on Day 1, followed by one-on-one meetings between Protalix management a

      3/24/25 6:50:00 AM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Protalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business Results

      Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, March 17, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the fiscal year ended December 31, 2024, and provided a business and clinical update.     "2024 was a record year in revenues from selling goods for Protalix, as we experienced increases in all three of our revenue streams, Chiesi, Pfizer and Brazil," said Dror Bashan, Protalix's Presi

      3/17/25 6:50:00 AM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025

      Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel, March 10, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the fiscal year ended December 31, 2024 and provide a business and clinical update on March 17, 2025. Management will host a conference call to discuss the financial results and provide an update on recent corporate and regulatory developments. Conference Call Detai

      3/10/25 6:50:00 AM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference

      Corporate presentation scheduled for Tuesday, February 11, 2025 at 10:15 AM EST CARMIEL, Israel, Feb. 4, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, today announced that it will attend and present at the 2025 BIO CEO & Investor Conference taking place February 10-11, 2025 at the New York Marriott Marquis in New York City. Management is scheduled to give a corporate overview at the BIO CEO & Investor Conference on Tuesday, February 11, 2025 at 10:15 AM EST at the Roya

      2/4/25 6:50:00 AM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Protalix BioTherapeutics Issues 2025 Letter to Stockholders

      CARMIEL, Israel, Dec. 23, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE-American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, today announced the following letter from its President and Chief Executive Officer, Dror Bashan, to its stockholders. December 23, 2024 Dear Protalix Stockholders, As we conclude 2024, I am filled with a sense of accomplishment as well as excitement for the year ahead. This past year, Protalix has achieved significant milestones that position our company for long-term growth. The success

      12/23/24 6:50:00 AM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa

      Application to label a less frequent dosing regimen at a dose of 2 mg/kg body weight administered every four weeks in adult patients with Fabry disease in European UnionPARMA, Italy and CARMIEL Israel, Dec. 9, 2024 /PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, and Protalix BioTherapeutics, Inc. (NYSE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that the European Medicines Agency (

      12/9/24 6:30:00 AM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results

      Company to host conference call and webcast today at 8:30 a.m. EST CARMIEL, Israel, Nov. 14, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE-American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended September 30, 2024, and provided a business and clinical update. "We are pleased to report that all eight cohorts of our phase I first-in-human study of PRX-115, our recombinant uricase candidate being developed for the treatment of uncontrolled gout, are now complete,

      11/14/24 6:50:00 AM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Protalix BioTherapeutics to Announce Third Quarter 2024 Financial and Business Results on November 14, 2024

      Company to host conference call and webcast at 8:30 a.m. EST CARMIEL, Israel, Nov. 7, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the quarter ended September 30, 2024 and provide a business and clinical update on November 14, 2024. Management will host a conference call to discuss the financial results and provide an update on recent corporate and regulatory developments. Conference Call Details

      11/7/24 6:50:00 AM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Levicept Appoints Eliot Forster as CEO

      Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for chronic pain indications, today announces the appointment of Eliot Forster as CEO. Founder and inventor of LEVI-04, Simon Westbrook, is to take the role of CSO. Eliot brings more than thirty years of experience in the biotech and pharmaceutical sectors, with considerable experience in deal making and finance. His appointment strengthens the Levicept leadership team as the company matur

      11/30/23 4:00:00 AM ET
      $IMCR
      $IMTX
      $PLX
      $FSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors

      Appointment effective as of September 14, 2023;Zeev Bronfeld to retire from the Board of Directors CARMIEL, Israel, Sept. 12, 2023 /PRNewswire / Protalix BioTherapeutics, Inc. (NYSE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that the Company's Board of Directors has appointed Eliot Richard Forster, Ph.D. to serve on the Board of Directors as its Chairman, effective as of September 14, 2023. In

      9/12/23 6:50:00 AM ET
      $IMTX
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Protalix BioTherapeutics Appoints Shmuel "Muli" Ben Zvi, Ph.D. to its Board of Directors

      CARMIEL, Israel, June 30, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE: PLX), announced today that the Company's Board of Directors has appointed Shmuel "Muli" Ben Zvi, Ph.D. to serve on the Company's Board of Directors. In addition to Dr. Ben Zvi's appointment as an independent director, he was also appointed to serve on the Company's Audit Committee and Compensation Committee. "We are excited to have Muli join our Board of Directors," commented Zeev Bronfeld, Chairman of Protalix's Board of Directors. "He brings extensive financial and economic knowle

      6/30/22 4:30:00 PM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Protalix BioTherapeutics Issues 2020 Letter to Shareholders

      CARMIEL, Israel, Dec. 30, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced the following letter from its President and Chief Executive Officer, Dror Bashan, to its shareholders and the investment community. Dear Protalix shareholders, As we look forward to 2021 with great anticipation, I want to take a moment to reflect on our transformational accomplishments this past year, which has been unlike any we could have imagined. Together

      12/30/20 6:50:00 AM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Protalix BioTherapeutics Inc. (DE) Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Sr. VP and CFO Rubin Eyal was granted 90,909 shares (SEC Form 4)

      4/A - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)

      11/5/24 5:00:15 PM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Sr. VP, Operations Naos Yaron

      4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)

      9/24/24 5:00:07 PM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sr. VP and CFO Rubin Eyal was granted 99,010 shares (SEC Form 4)

      4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)

      9/24/24 5:00:09 PM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Bashan Dror was granted 263,960 shares (SEC Form 4)

      4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)

      4/3/24 5:30:27 PM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Bashan Dror bought $90,484 worth of shares (64,516 units at $1.40), increasing direct ownership by 95% to 132,516 units (SEC Form 4)

      4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)

      10/20/23 6:50:07 AM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Boudes Pol F

      4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)

      10/3/23 5:00:58 PM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Schwartz Aharon

      4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)

      10/3/23 5:00:32 PM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Ben Zvi Shmuel

      4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)

      10/3/23 5:00:50 PM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Melincoff Gwen A

      4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)

      10/3/23 5:00:54 PM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Bar-Shalev Amos

      4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)

      10/3/23 5:00:51 PM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care